schizophrenia
Conditions
Interventions
Brexpiprazole 2mg/day (6 weeks, open label study)
Sponsors
Fujita Health University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The patient understands and agrees to all the risks and all the benefits of the proposed study 2. inpatient and outpatient 3. male and femele 4. PANSS-EC total score of. >=14 with one or more individual items scoring>=4 and CGI-S>=4 5. not receiving antipsychotic for>=2 days before the study or receiving antipsychotic (Chlorpromazine equivalent doses<=200mg/day) for>=3 days before the study
Exclusion criteria
Exclusion criteria: 1. the patient with coma 2. the patient receiving anesthetic agent or barbiturate 3. the patient receiving epinephrine 4. the patient receiving psychostimulant 5. the patient having allergy brexpiprazole 6, the patient with DM 7. the patient with pregnancy 8. the patient with breast-feeding 9. the patient receiving clozapine 10. the patient suitable for clozapine 11. the patient who the clinician do not suggest to entry the study 12. the patient with mental retardation 13. the patient with dementia 14. the patient with personality disorder 15. the patient with organic brain disease and/or severe physical disease 16. the patient receiving paroxetine 17. the patient receiving carbamazepine 18. the patient receiving electroconvulsive therapy within 6 months before the study 19. the patient receiving long-acting injectable antipsychotics within 6 months before the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All causes discontinuation | — |
Secondary
| Measure | Time frame |
|---|---|
| Discontinuation due to adverse events, discontinuation due to inefficacy, the improvement of psychopathology, individual adverse events | — |
Countries
Japan
Contacts
Public ContactTaro Kishi
Fujita Health University School of Medicine Psychiatry
Outcome results
None listed